Measures currently being taken against COVID-19 are the only means of containing and suppressing the virus. Until a vaccine is made and tested, progress will remain slow. As we’ve seen over the past month, the concerns around this novel coronavirus will only grow as markets around the world are getting crushed.
China first faced the outbreak of the novel coronavirus, and now it has spread across the world. Global infections of roughly 394,000 people have been reported. There are currently 273,000 active cases of the coronavirus and over 120,000 closed cases. Of those with outcomes, nearly 103,000 of those infected have recovered, while about 17,000 deaths have been reported.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and where their stocks stand now.
Mylan N.V. (NASDAQ: MYL) stock was up over 4% at $16.47 on Tuesday, in a 52-week range of $12.75 to $28.88. The consensus price target is $23.93.
Novavax Inc. (NASDAQ: NVAX) traded up about 25% to $13.43, in a 52-week range of $3.54 to $17.71. The consensus price target is $14.00.
Aytu BioScience Inc. (NASDAQ: AYTU) shares were up 7.5% to $2.01. The 52-week range is $0.34 to $2.99, and the consensus price target is $4.88.
Altimmune Inc. (NASDAQ: ALT) shares were up less than 1% to $2.97, in a 52-week range of $1.51 to $4.45. The consensus price target is $13.00.
NanoViricides Inc. (NYSE: NNVC) stock pushed 4% lower to $5.88. The 52-week range is $1.27 to $19.20.
Moderna Inc. (NASDAQ: MRNA) shares traded down 7% at $24.70, in a 52-week range of $11.54 to $36.00. The consensus price target is $33.44.
Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares were up 6% at $7.03. The 52-week range is $1.92 to $19.36, and the consensus price target is $10.43.
Gilead Sciences Inc. (NASDAQ: GILD) shares were up about 1% at $73.35. The 52-week range is $60.89 to $85.97. The consensus price target is $74.91.
Sanofi (NASDAQ: SNY) shares were up about 4% at $40.19, in a 52-week range of $37.62 to $51.84. The consensus price target is $56.88.
Quest Diagnostics Inc. (NYSE: DGX) stock was up about 4% at $78.06, in a 52-week range of $73.21 to $118.58. The consensus price target is $110.43.
Co-Diagnostics Inc. (NASDAQ: CODX) stock was down 12% at $8.30. It has a 52-week range of $0.69 to $21.75 and a consensus analyst target of $19.00.
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) was down about 1% at $452.20, with a 52-week range of $271.37 to $518.00. The consensus price target is $475.00.
24/7 Wall St.Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
